Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of bisphosphonates in cancer patients.
Body JJ, Coleman RE, Piccart M. Body JJ, et al. Among authors: piccart m. Cancer Treat Rev. 1996 Jul;22(4):265-87. doi: 10.1016/s0305-7372(96)90020-1. Cancer Treat Rev. 1996. PMID: 9025784 Review. No abstract available.
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Piccart MJ, et al. J Clin Oncol. 1997 Sep;15(9):3149-55. doi: 10.1200/JCO.1997.15.9.3149. J Clin Oncol. 1997. PMID: 9294478 Clinical Trial.
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Hamilton A, Roy JA, Beex L, Piccart M, Mauriac L, Coleman R, Paridaens R, Boes GH, van Vreckem A, Palmer P, Klijn J. Hamilton A, et al. Among authors: piccart m. Breast Cancer Res Treat. 2000 Mar;60(2):181-8. doi: 10.1023/a:1006398518037. Breast Cancer Res Treat. 2000. PMID: 10845281 Clinical Trial.
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Biganzoli L, et al. Among authors: piccart mj. J Clin Oncol. 2002 Jul 15;20(14):3114-21. doi: 10.1200/JCO.2002.11.005. J Clin Oncol. 2002. PMID: 12118025 Clinical Trial.
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A, Hamilton A, Piccart M. Biganzoli L, et al. Among authors: piccart m. Cancer. 2003 Jan 1;97(1):40-5. doi: 10.1002/cncr.10914. Cancer. 2003. PMID: 12491503 Free article. Clinical Trial.
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A; EORTC-BCG-IDBBC-NDDG. Efficace F, et al. Among authors: piccart m. Eur J Cancer. 2004 May;40(7):1021-30. doi: 10.1016/j.ejca.2004.01.014. Eur J Cancer. 2004. PMID: 15093577 Clinical Trial.
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M; European Organization for Research and Treatment of Cancer Breast Cancer Group. Bottomley A, et al. Among authors: piccart m. J Clin Oncol. 2004 Jul 1;22(13):2576-86. doi: 10.1200/JCO.2004.02.037. J Clin Oncol. 2004. PMID: 15226325 Clinical Trial.
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Von Minckwitz G, Leroy JY, Durbecq V, Isola J, Aapro M, Piccart MJ, Larsimont D. Di Leo A, et al. Among authors: piccart mj. Breast Cancer Res Treat. 2004 Aug;86(3):197-206. doi: 10.1023/B:BREA.0000036783.88387.47. Breast Cancer Res Treat. 2004. PMID: 15567936 Clinical Trial.
616 results